Injection of IL-12- and IL-18-encoding plasmids ameliorates the autoimmune pathology of MRL/Mp-Tnfrsf6lpr mice: Synergistic effect on autoimmune symptoms

International Immunology

Volumn 18, Issue 12, 2006, Pages 1779-1787

  Neumann, Detlef ^a   Tschernig, Thomas ^a   Popa, Daniela ^a   Schmiedl, Andreas ^a   de Lema, Guillermo Pérez ^b   Resch, Klaus ^a   Martin, Michael Uwe ^a,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; PLASMID DNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA VECTOR; DRUG POTENTIATION; DRUG TARGETING; FEMALE; IMMUNOPATHOLOGY; IN VITRO STUDY; KIDNEY INJURY; LYMPHADENOPATHY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL;

ANIMALS; AUTOIMMUNE DISEASES; DNA, COMPLEMENTARY; FEMALE; INTERLEUKIN-12; INTERLEUKIN-18; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPH NODES; MICE; MICE, INBRED MRL LPR; ORGAN SIZE; PLASMIDS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA;

EID: 33845372494     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxl112     Document Type: Article

References (49)

1. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A. and Nagata, S. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.
2. Criscione, L. G. and Pisetsky, D. S. 2003. B lymphocytes and systemic lupus erythematosus. Curr. Rheumatol. Rep. 5:264.
3. Richardson, B. 2003. DNA methylation and autoimmune disease. Clin. Immunol. 109:72.
4. Bleesing, J. J. 2003. Autoimmune lymphoproliferative syndrome (ALPS). Curr. Pharm. Design. 9:265.
5. Bossu, P., Singer, G. G., Andres, P., Ettinger, R., Marshak-Rothstein, A. and Abbas, A. K. 1993. Mature CD4+ T lymphocytes from MRL/lpr mice are resistant to receptor-mediated tolerance and apoptosis. J. Immunol. 151:7233.
6. Singer, G. G. and Abbas, A. K. 1994. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365.
7. Van Parijs, L. and Abbas, A. K. 1996. Role of Fas-mediated cell death in the regulation of immune responses. Curr. Opin. Immunol. 8:355.
8. Mixter, P. F., Russell, J. Q., Morrissette, G. J., Charland, C., Aleman-Hoey, D. and Budd, R. C. 1999. A model for the origin of TCR-alphabeta+ B220+ cells based on high affinity TCR signals. J. Immunol. 162:5747.
9. Morse, H. C. III, Davidson, W. F., Yetter, R. A., Murphy, E. D., Roths, J. B. and Coffman, R. L. 1982. Abnormalities induced by the mutant gene Ipr: Expansion of a unique lymphocyte subset. J. Immunol. 129:2612.
10. Andrews, B. S., Eisenberg, R. A., Theofilopoulos, A. N. et al. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1198.
11. Cohen, P. L. and Eisenberg, R. A. 1991. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243.
12. Korner, H., Cretney, E., Wilhelm, P. et al. 2000. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J. Exp. Med. 191:89.
13. Kim, N., Ussin, L., Cheng, X., Murali, R. and Sullivan, K. E. 2002. TNFalpha inhibition in MRL/lpr mice ameliorates pulmonary but not renal disease. J. Autoimmun. 19:215.
14. Balomenos, D., Rumold, R. and Theofilopoulos, A. N. 1998. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101:364.
15. Peng, S. L., Moslehi, J. and Craft, J. 1997. Roles of interferongamma and interleukin-4 in murine lupus. J. Clin. Invest. 99:1936.
16. Schwarting, A., Wada, T., Kinoshita, K., Tesch, G. and Kelley, V. R. 1998. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 161:494.
17. Dinarello, C. A. 1999. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J. Allergy Clin. Immunol. 103:11.
18. Dinarello, C. A. 2000. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw. 11:483.
19. Huang, F. P., Feng, G. J., Lindop, G., Stott, D. I. and Liew, F. Y. 1996. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRLinverted question markMP-lprinverted question marklpr mice. J. Exp. Med. 183:1447.
20. Fan, X., Oertli, B. and Wuthrich, R. P. 1997. Up-regulation of tubular epithelial interleukin-12 in autoimmune MRL-Fas(lpr) mice with renal injury. Kidney Int. 51:79.
21. Schwarting, A., Tesch, G., Kinoshita, K., Maron, R., Weiner, H. L. and Kelley, V. R. 1999. IL-12 drives IFN-gamma-dependent autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 163:6884.
22. Yasuda, T., Yoshimoto, T., Tsubura, A. and Matsuzawa, A. 2001. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRLFAS(lprcg)/FAS(lprcg) mice. Cell. Immunol. 210:77.
23. Kikawada, E., Lenda, D. M. and Kelley, V. R. 2003. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology. J. Immunol. 170:3915.
24. Neumann, D., Del Giudice, E., Ciaramella, A., Boraschi, D. and Bossu, P. 2001. Lymphocytes from autoimmune MRL lpr/lpr mice are hyperresponsive to IL-18 and overexpress the IL-18 receptor accessory chain. J. Immunol. 166:3757.
25. Wildbaum, G., Youssef, S., Grabie, N. and Karin, N. 1998. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J. Immunol. 161:6368.
26. Kinoshita, K., Yamagata, T., Nozaki, Y. et al. 2004. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J. Immunol. 173:5312.
27. Prud'homme, G. J. and Chang, Y. 1999. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther. 6:771.
28. Piccirillo, C. A. and Prud'homme, G. J. 2003. Immune modulation by plasmid DNA-mediated cytokine gene transfer. Curr. Pharm. Design. 9:83.
29. Putterman, C. and Diamond, B. 1998. Immunization with a peptide surrogate for double-stranded DNA (dsDNA) induces autoantibody production and renal immunoglobulin deposition. J. Exp. Med. 188:29.
30. Kimura, M., Mohri, H., Shimada, K., Wakabayashi, T., Kanai, Y. and Matsuzawa, A. 1990. Serological and histological characterization of the new mutant strain of lpr mice, CBA/KlJms-lprcg/lprcg. Clin. Exp. Immunol. 79:123.
31. Theofilopoulos, A. N. and Dixon, F. J. 1981. Etiopathogenesis of murine SLE. Immunol. Rev. 55:179.
32. Bossu, P., Neumann, D., Del Giudice, E. et al. 2003. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc. Natl Acad. Sci. USA 100:14181.
33. Coon, B., An, L. L., Whitton, J. L. and von Herrath, M. G. 1999. DNA immunization to prevent autoimmune diabetes. J. Clin. Invest. 104:189.
34. Garren, H., Ruiz, P. J., Watkins, T. A. et al. 2001. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15:15.
35. Ghoreschi, K. and Rocken, M. 2003. Molecular and cellular basis for designing gene vaccines against inflammatory autoimmune disease. Trends Mol. Med. 9:331.
36. Hagiwara, E., Okubo, T., Aoki, I. et al. 2000. IL-12-encoding plasmid has a beneficial effect on spontaneous autoimmune disease in MRL/MP-lpr/ lpr mice. Cytokine 12:1035.
37. Tisch, R., Wang, B., Weaver, D. J. et al. 2001. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J. Immunol. 166:2122.
38. Wolfe, T., Bot, A., Hughes, A. et al. 2002. Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: Addition of IL-4 increases safety. Eur. J. Immunol. 32:113.
39. Sun, Y., Chen, H. M., Subudhi, S. K. et al. 2002. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med. 8:1405.
40. Jordan, J. A., Guo, R. F., Yun, E. C. et al. 2001. Role of IL-18 in acute lung inflammation. J. Immunol. 167:7060.
41. Izui, S., Kelley, V. E., Masuda, K., Yoshida, H., Roths, J. B. and Murphy, E. D. 1984. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J. Immunol. 133:227.
42. Esfandiari, E., McInnes, I. B., Lindop, G. et al. 2001. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J. Immunol. 167:5338.
43. Wozniacka, A., Lesiak, A., Narbutt, J., McCauliffe, D. P. and Sysa-Jedrzejowska, A. 2006. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15:268.
44. Park, M. C., Park, Y. B. and Lee, S. K. 2004. Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus. Clin. Rheumatol. 23:225.
45. Wong, C. K., Li, E. K., Ho, C. Y. and Lam, C. W. 2000. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 39:1078.
46. Tokano, Y., Morimoto, S., Kaneko, H. et al. 1999. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1- and Th2-derived cytokines. Clin. Exp. Immunol. 116:169.
47. Wildbaum, G., Youssef, S. and Karin, N. 2000. A targeted DNA vaccine augments the natural immune response to self TNF-alpha and suppresses ongoing adjuvant arthritis. J. Immunol. 165:5860.
48. Youssef, S., Maor, G., Wildbaum, G., Grabie, N., Gour-Lavie, A. and Karin, N. 2000. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J. Clin. Invest. 106:361.
49. Blank, M., Krause, I., Wildbaum, G., Karin, N. and Shoenfeld, Y. 2003. TNFalpha DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome. Lupus 12:546.